These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 7107390)
21. Enhancement of the action of alkylating agents by single high, or chronic low doses of misonidazole. McNally NJ; Hinchliffe M; de Ronde J Br J Cancer; 1983 Aug; 48(2):271-8. PubMed ID: 6882665 [TBL] [Abstract][Full Text] [Related]
22. Studies on the mechanism of chemosensitization by misonidazole in vitro. Taylor YC; Bump EA; Brown JM Int J Radiat Oncol Biol Phys; 1982; 8(3-4):705-8. PubMed ID: 7107402 [TBL] [Abstract][Full Text] [Related]
23. Effect of partition coefficient on the ability of nitroimidazoles to enhance the cytotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Hirst DG; Brown JM; Hazlehurst JL Cancer Res; 1983 May; 43(5):1961-5. PubMed ID: 6682009 [TBL] [Abstract][Full Text] [Related]
24. Effect of tumor size on S-2-(3-aminopropylamino)ethylphosphorothioic acid and misonidazole alteration of tumor response to cyclophosphamide. Milas L; Ito H; Hunter N Cancer Res; 1983 Jul; 43(7):3050-6. PubMed ID: 6303574 [TBL] [Abstract][Full Text] [Related]
25. Sensitization of normal and malignant tissue to cyclophosphamide by nitroimidazoles with different partition coefficients. Hirst DG; Hazlehurst JL; Brown JM Br J Cancer; 1984 Jan; 49(1):33-42. PubMed ID: 6229264 [TBL] [Abstract][Full Text] [Related]
26. Misonidazole increases the toxicity of BCNU for hypoxic cells. Tannock I; Guttman P Int J Radiat Oncol Biol Phys; 1982; 8(3-4):663-6. PubMed ID: 7107395 [TBL] [Abstract][Full Text] [Related]
27. The mechanisms of cytotoxicity and chemosensitization by misonidazole and other nitroimidazoles. Brown JM Int J Radiat Oncol Biol Phys; 1982; 8(3-4):675-82. PubMed ID: 7050043 [TBL] [Abstract][Full Text] [Related]
28. Direct effects of the hypoxic cell sensitizer misonidazole on colony formation in a human tumor cloning assay. Scheithauer W; Von Hoff DD; Forseth B; Cowan JD Cancer Drug Deliv; 1986; 3(1):15-24. PubMed ID: 3955496 [TBL] [Abstract][Full Text] [Related]
29. Skin sensitization by misonidazole: a demonstration of uniform mild hypoxia. Stewart FA; Denekamp J; Randhawa VS Br J Cancer; 1982 Jun; 45(6):869-77. PubMed ID: 7093121 [TBL] [Abstract][Full Text] [Related]
30. Chemosensitization of the nitrosoureas by 2-nitroimidazoles in the subcutaneous 9L tumor model: pharmacokinetic and structure-activity considerations. Wong KH; Wallen CA; Wheeler KT Int J Radiat Oncol Biol Phys; 1990 May; 18(5):1043-50. PubMed ID: 2140824 [TBL] [Abstract][Full Text] [Related]
31. Growth delay in small EMT6 spheroids induced by cytotoxic drugs and its modification by misonidazole pretreatment under hypoxic conditions. Twentyman PR Br J Cancer; 1982 Apr; 45(4):565-70. PubMed ID: 7073947 [TBL] [Abstract][Full Text] [Related]
32. The combination of 5-fluorouracil with misonidazole in patients with advanced colorectal cancer. Spooner D; Bugden RD; Peckham MJ; Wist EA Int J Radiat Oncol Biol Phys; 1982; 8(3-4):387-9. PubMed ID: 7107357 [TBL] [Abstract][Full Text] [Related]
33. Misonidazole hypoxic cytotoxicity and chemosensitization in two cell lines with different intracellular glutathione levels. DeGraff WG; Russo A; Friedman N; Mitchell JB Eur J Cancer; 1990 Jan; 26(1):17-20. PubMed ID: 2138473 [TBL] [Abstract][Full Text] [Related]
34. [Recent advances in hypoxic cell radiosensitizer]. Ono K; Takahashi M; Nishidai T; Shibamoto Y; Abe M Gan No Rinsho; 1983 Oct; 29(13):1608-12. PubMed ID: 6230470 [TBL] [Abstract][Full Text] [Related]
35. Mechanism of melphalan crosslink enhancement by misonidazole pretreatment. Taylor YC; Sawyer JM; Hsu B; Brown JM Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1603-7. PubMed ID: 6480448 [TBL] [Abstract][Full Text] [Related]
36. Cytotoxicity of metronidazole (Flagyl) and misonidazole (Ro-07-0582): enhancement by lactate. Mahood JS; Willson RL Br J Cancer; 1981 Mar; 43(3):350-4. PubMed ID: 7225286 [TBL] [Abstract][Full Text] [Related]
37. Enhancement of the effect of cytotoxic drugs by radiosensitizers. Martin WM; McNally NJ; De Ronde J Br J Cancer; 1981 Jun; 43(6):756-66. PubMed ID: 7248157 [TBL] [Abstract][Full Text] [Related]
38. Clinical trials of radiosensitizers: what should we expect? Brown JM Int J Radiat Oncol Biol Phys; 1984 Mar; 10(3):425-9. PubMed ID: 6231272 [TBL] [Abstract][Full Text] [Related]
39. Potentiation of melphalan activity in the KHT sarcoma by the radiosensitizer RSU 1069. Siemann DW; Maddison K; Wolf K Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1657-60. PubMed ID: 6548212 [TBL] [Abstract][Full Text] [Related]